---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293507347.md"
description: "LB Pharmaceuticals shares are trading higher after the company announced accelerated timing for topline results from the Phase 3 NOVA-2 trial of LB-102 in Schizophrenia."
datetime: "2026-07-22T17:55:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293507347.md)
  - [en](https://longbridge.com/en/news/293507347.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293507347.md)
---

# 

LB Pharmaceuticals shares are trading higher after the company announced accelerated timing for topline results from the Phase 3 NOVA-2 trial of LB-102 in Schizophrenia.

### Related Stocks

- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)

## Related News & Research

- [LB Pharmaceuticals prices USD 150 million private placement at USD 34.94 per share](https://longbridge.com/en/news/294206557.md)
- [LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained](https://longbridge.com/en/news/293644868.md)
- [LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timeline](https://longbridge.com/en/news/293470551.md)
- [LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High  - Time to Buy?](https://longbridge.com/en/news/283472672.md)
- [LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | LBRX Stock News](https://longbridge.com/en/news/292356794.md)